Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes

Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.

India Commercial

Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

Asia Pacific Deals

Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry

The advisory committee route for approving a first biosimilar to a reference product is no longer necessarily the norm, going by FDA's recent approval of Mylan/Biocon's pegfilgrastim-jmdb, which references Amgen’s Neulasta; agency’s view that a meeting was not needed should encourage other biosimilar aspirants.

Biosimilars Advisory Committees

Sun’s Halol Site Out Of Compliance Rut, Could Add Some SPARC Too

Sun's Halol manufacturing facility is over the compliance hump, receiving an EIR [Establishment Inspection Report] from the US FDA. The site, seen as core to India's top ranked firm's promising filings, including injectables, is also expected to lift the prospects of Sun's spin-off R&D arm, SPARC.

Manufacturing Compliance

Sanofi Takes On Infringing Look-Alike In India

Sanofi has sought to block an alleged infringer's attempt to ride on its trademarks, trade name and logo in India; the French multinational views these activities as intended to cause confusion among consumers.

Trademarks India

Cipla Opens Up To Crowd Sourcing Innovation

Cipla has outlined its intent to incubate disruptive ideas in the healthcare space, along the lines of similar initiatives to accelerate innovation from US/European big pharma. It hopes that this "culture" will expand in India.

India Innovation
See All
Advertisement
UsernamePublicRestriction

Register